MedTrace Logo

Concurent Chemoradiotherapy in Head and Neck Cancers

NCT04780750 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-03-03

No results posted yet for this study

Summary

To compare the efficacy and toxicities of the combination between weekly docitaxel and cisplatin (every3 week) concurrent with radiation versus the standard concurrent chemoradiotherapy with high dose cisplatin (100mg\\m2) for locally advanced HNSCC

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG

Docetaxel

Arm A (tested regimen): concurrent chemoradiotherapy with weekly docitaxel (20 mg\\m2) and cisplatin (80mg\\m2 every 3 weeks)

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • doAA ABDELALEEM, Master · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-04-01
Completion
2022-09-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04780750 on ClinicalTrials.gov